+

WO1991007993A1 - Facteurs anti-inflammatoires et anti-adhesifs - Google Patents

Facteurs anti-inflammatoires et anti-adhesifs Download PDF

Info

Publication number
WO1991007993A1
WO1991007993A1 PCT/AU1990/000573 AU9000573W WO9107993A1 WO 1991007993 A1 WO1991007993 A1 WO 1991007993A1 AU 9000573 W AU9000573 W AU 9000573W WO 9107993 A1 WO9107993 A1 WO 9107993A1
Authority
WO
WIPO (PCT)
Prior art keywords
gmp140
protein
mammal
adhesion
blood cells
Prior art date
Application number
PCT/AU1990/000573
Other languages
English (en)
Inventor
Mathew Vadas
Michael Berndt
Original Assignee
Mathew Vadas
Michael Berndt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mathew Vadas, Michael Berndt filed Critical Mathew Vadas
Publication of WO1991007993A1 publication Critical patent/WO1991007993A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178—Lectin superfamily, e.g. selectins

Definitions

  • the present invention relates generally to a method for interfering with various activities of blood cells in a mammal and thereby inhibiting, reducing or otherwise controlling an inflammatory response and/or reducing, preventing and/or inhibiting the adhesion of blood cells to endothelial cells.
  • the present invention is also directed to pharmaceutical compositions useful in such a method comprising granule membrane protein (GMP) 140 and/or its derivatives and like proteins.
  • GMP granule membrane protein
  • Granule membrane protein (GMP) 140 is a 140 Kd glycoprotein found in platelet alpha granules and in Wiebel-Palade bodies of endothelial cells (1,2,3) and is expressed on both platelet and endothelial cell membrane surfaces following cell activation (4,5,6). This property has been employed to image athersclerotic plaques in vivo using labelled monoclonal antibodies to GMP140 (Internation Patent Application No.
  • soluble GMP140 affects the ability of some white blood cells such as neutrophils to assume an activated phenotype and that it reduces, prevents and/or inhibits adhesion of blood cells, such as activated neutrophils, to endothelium. Furthermore, it prevents the activation of these cells by exogenous stimuli.
  • the present invention is useful, therefore, in controlling an' ' inflammatory response and in reducing, preventing and/or inhibiting adhesion of blood cells to endothelium as is desired in the treatment of, but not necessarily limited to, vascular injury after reperfusion of arteries, uncontrolled inflammatory reactions, for example septicemia, and to aid recovery from frost bite or reattachment of severed limbs.
  • one aspect of the present invention contemplates a method for inhibiting, reducing or otherwise controlling an inflammatory response in a mammal comprising administering to said mammal an effective amount of GMP140 and/or GMP140-like protein and optionally in combination with an agonist for GMP140 and/or its like protein.
  • the present invention is directed to a method for inhibiting, reducing or otherwise controlling an inflammatory response in a mammal comprising administering to said mammal an effective amount of GMP140 and/or GMP140-like protein and optionally in combination with an agonist for GMP140 and/or GMP140-like
  • SUBSTITUTE SHEET protein for a time and under conditions sufficient for the function of white blood cells involved in said inflammatory response to be inhibited and thereby controlling said inflammatory response.
  • Yet another aspect of the present invention relates to a method for reducing, preventing and/or inhibiting adhesion of blood cells to endothelial cells in a mammal which method comprises administering to said mammal a blood cell adhesion-reducing, -preventing and/or - inhibiting effective amount of GMP140 and/or GMP-like protein for a time and under conditions sufficient to reduce, prevent and/or inhibit adhesion of blood cells to endothelial cells.
  • Still yet another aspect of the present invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising GMP140 and/or GMP140-like protein and optionally agonistic and/or synergistic factors to GMP140 and/or its like protein and one or more pharmaceutically acceptable carriers and/or diluents.
  • a further aspect of the present invention relates to the use of GMP140 and/or GMP140-Iike protein in the manufacture of a medicament for the reduction, prevention and/or inhibition of adhesion of blood cells to endothelial cells and/or for the inhibiting, reducing or otherwise controlling of an inflammatory response in a mammal.
  • the mammal is a human.
  • the present invention is described using neutrophils as the preferred white blood cells. This is done, however, with the understanding that the present invention extends to any white blood cell involved in an inflammatory response and whose function may be affected by GMP140 and/or its like protein in such a way as to inhibit, reduce or otherwise control the inflammatory response.
  • the present invention is also directed to the affect on more than one type of white blood cell.
  • Figure 1 is a graphical representation showing that increasing concentrations of GMP140 in solution inhibits adhesion of activated neutrophils to endothelial cells.
  • Figure 2 is a graphical representation showing the generation of 0 2 " anions of either unactivated neutrophils (NIL) or neutrophils activated by 100 U/ml of TNF- ⁇ (TNF).
  • NIL unactivated neutrophils
  • TNF- ⁇ TNF- ⁇
  • Cells are added to uncoated (plastic) microtitre plates or one coated with fibrinogen (FBN) or GMP140 (GMP).
  • FBN fibrinogen
  • GMP140 GMP140
  • 0 2 * generation is measured after 30' and bars are arithmetic mean of 9 replicates of 3 experiments ⁇ SEM.
  • 0 2 " generation in GMP group differs significantly (p ⁇ 0.005) from FBN or plastic.
  • Figure 3 is a graphical representation showing the effect of increasing doses of GMP140 on 0 2 " generation and adhesion of TNF- ⁇ activated neutrophils.
  • Increasing doses of GMP140 are used to coat plastic microtitre plates before addition of neutrophils.
  • Adhesion to GMP140 and 0 2 " generation appear inversely related.
  • Simi-Uar results are obtained with unactivated neutrophils.
  • the first aspect of the present invention is predicated, in part, on the surprising discovery that when neutrophils are added to plastic microtitre plates coated with GMP140, little 0 2 " generation is seen even when
  • SUBSTITUTE SHEET neutrophils are activated with TNF- ⁇ (Fig. 2).
  • neutrophils added to plastic wells or fibrinogen coated microtitre wells produce significant levels of 0 2 " either when unactivated or activated with TNF- ⁇ (Fig. 2).
  • the lack of 0 2 " production by neutrophils in GMP140 coated wells is observed even though neutrophils adhere to GMP140 vigorously (Fig. 3) - suggesting adhesion to GMP140 is qualitatively different from that to plastic or fibrinogen in not allowing 0 2 " production.
  • neutrophils adherent to GMP140 also fail to spread and are maintained as a rounded phenotype.
  • Soluble GMP140 also prevents 0 2 ⁇ production as shown in Table 4. Soluble GMP140 inhibits 0 2 " production of neutrophils added to plastic even when the cells are activated by TNF- ⁇ . This inhibition is prevented by affinity purified rabbit anti-GMP140 Fab' but not by control Fab' antibodies. It is also shown in Table 4 that GMP140 is effective even when added 15' after the experiment begins suggesting that it also inhibits the ongoing generation of 0 2 ⁇ .
  • GMP140 is a natural anti-inflammatory substance for neutrophils and that it moderates other aspects of neutrophil function such as degranulation and cytotoxicity.
  • GMP140 or its like protein will be a useful anti-inflammatory agent and have use in acute or chronic inflammatory conditions.
  • the depletion of GMP140 stores may be responsible for sequelae of acute stress, trauma or inflammatory reactions, such as the respiratory distress syndrome, and use of soluble forms of this protein may be beneficial.
  • GMP140 As the action of GMP140 extends to eosinophils and basophils it may also be useful to prevent or moderate the activation of these cells which play a dominant role in the pathogenesis of allergic reactions and, in particular, asthma.
  • the anti-inflammatory effect of GMP140 extends to monocyte function in general and in particular, to the role of monocyte 0 2 ⁇ generating systems on the oxidation of lipids enhancing their uptake by the scavenger receptor and leading to accelerated atherogenesis.
  • Another aspect of the present invention is predicated in part on the surprising discovery that soluble GMP140 inhibits the adhesion of blood cells, and in particular neutrophils, to endothelial cells.
  • soluble GMP140 as used throughout the present specification is meant a GMP140 lacking a transmembrane domain and, therefore, secreted from platelets or endothelial cells. The term also extends to solubilized membrane associated GMP140 and to recombinant and synthetic forms of GMP140.
  • blood cells herein is used in its broadest sense to mean any cell circulating in the blood and includes, but is not necessarily limited to, neutrophils and monocytes.
  • the present invention also extends to derivatives of' GMP140.
  • derivatives of GMP140 is meant any alteration to primary, secondary or tertiary structure of naturally or non-naturally occurring GMP140 or any alteration which affects the natural or non-natural activity or function of GMP140 or which enhances or delimits its anti-adhesive and/or its anti-inflammatory properties.
  • Derivatives of GMP140 contemplated herein include, but are not limited to, those affecting the extent of glycosylation and/or association and/or
  • GMP140 SUBSTITUTESHEET conjugation of GMP140 or its derivatives with other molecules (eg. lipids or proteins or polypeptides), and to derivatives where the polypeptide portion of GMP140 has been altered. All such derivatives may also promote, stabilise and/or enhance the function of GMP140.
  • other molecules eg. lipids or proteins or polypeptides
  • the present invention extends to naturally occurring soluble or solubilized GMP140 and to naturally and non-naturally occurring derivatives of GMP140 including those with or without glycosylation, association with other molecules and/or an altered amino acid sequence of the polypeptide portion of GMP140.
  • non-natural GMP140 is meant to include its recombinant and/or synthetic forms. All such derivatives and non- natural forms of GMP140 are encompassed herein by the term "GMP140-like proteins".
  • the GMP140-like protein is a fragment of GMP140 having anti-inflammatory and/or anti-adhesion activity.
  • compositions comprising GMP140 and/or its like protein and one or more pharmaceutically acceptable carriers and/or diluents.
  • the pharmaceutical compositions contemplated herein may comprise solely GMP140 or GMP140-like protein or may comprise combinations of GMP140 and its derivatives or combinations of different derivatives, the combination desired depending on the relevant anti-adhesive or anti- inflammatory activities and/or other properties of GMP140 and its derivatives.
  • the pharmaceutical compositions may also contain agonistic and/or synergistic factors of GMP140 or its derivatives.
  • One source of such agonists and/or synergists may be peptide, polypeptide or glycopeptide derivatives of GMP140 or peptide, polypeptide or glycopeptide derivatives of complementary molecules to GMP140 and/or its proteins.
  • Such complementary molecules may be, but are not necessarily limited to, polypeptides or glycopeptides which can associate with GMP140 or its derivatives.
  • the active ingredients of a pharmaceutical composition comprising GMP140 or the like are contemplated to exhibit excellent therapeutic activity in reducing, preventing and/or inhibiting adhesion of blood cells to endothelial cells or in inhibiting, reducing or otherwise controlling an inflammatory response when administered in amounts, although depending on the particular case, of about 0.001 • ⁇ g to about 200 mg per kilogram of body weight of the mammal per day. Dosage procedures, however, may be adjusted to provide the optimum therapeutic response and more or less of the active component may need to be administered. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
  • the active compound may be administered in a convenient manner such as by the intravenous (where water soluble), intramuscular, subcutaneous intranasal, intradermal, pulmonary (eg via lungs) or suppository routes or implanting (eg using slow release molecules).
  • the active ingredients which comprise GMP140 or the like may be required to be coated in a material to protect said ingredients from the action of enzymes, acids and other natural conditions which may inactivate said ingredients.
  • the pharmaceutical forms suitable for in ectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (eg glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of superfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilisation.
  • dispersions are prepared by incorporating the various sterilised active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like.
  • the use of such media and agents for-pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • the present invention is directed to the use of the subject pharmaceutical compositions in mammals, and in particular, humans.
  • the present invention also extends to the use of GMP140 and/or its like proteins in the manufacture of a medicament for the reductions, prevention and/or inhibition of adhesion of blood cells to endothelial cells and/or the inhibiting or otherwise controlling of an inflammatory response in a mammal.
  • Endothelial cells are prepared by collagenase treatment of human umbilical vein. The cells are grown on gelatin coated plastic and used within 6 days following establishment of culture. Cells are harvested by trypsin-EDTA treatment replated at 2 x 10 4 cells/well in microtitre wells and grown to confluence overnight. Before use in the assay, the monolayers are washed in
  • Neutrophils are prepared from freshly drawn blood by destran sedimentation and ficol-hypaque separation. The erythrocytes are removed by hypotonic shock.
  • the GMP140 diluted in RPMI 1640 - 2.5% (v/v) FCS are added to the monolayers of endothelial cells either with or without tumour necrosis factor (TNF). Neutrophils are then added and incubated for 30 minutes at 37°C, 5% C0 2 . The supernatant is removed, the cells stained with Rose Bengal and the adherence ⁇ SEM (standard error of the mean) is given either as optical density (OD) or a percent adherence for triplicate determinations performed for each group.
  • Adhesion assays are as defined in references 10 and 11. Pure GMP140 (12), as verified by N-terminal sequencing, was passed through a column to remove detergent and used immediately.
  • FIG. 1 show that soluble GMP140 inhibits the adhesion of neutrophils to endothelial cells.
  • GMP140, RNF (lOU/ml) and neutrophils are incubated together with the endothelial monolayers for 30 minutes at 37°C before the level of adherence determined as described.
  • SUBSTITUTESHEET The anti-adhesive property is also observed both when GMP140 is added to the adhesion reaction as well as when neutrophils are pre-coated with this molecule as shown in Table 2.
  • the neutrophils are incubated for 15 minutes at 37°C with GMP140, washed once and then added to the endothelial monolayers together with lOU/ml TNF, incubated for 20 minutes at 37°C and adherence determined.
  • PMN were pretreated with GMP140 or control medium for 15 minutes at 37°C, immediately placed on ice, diluted in ice cold medium and centrifuged for 15 seconds at 12,000g. The cells were resuspended and added to HUVES together with TNF- ⁇ .
  • GMP140 is preincubated with rabbit anti-GMP140 for 15 minutes 37 C C. The mixture is then added to endothelial monolayers together with neutrophils and TNF. Adherence levels are determined 20 minutes later.
  • FMLP (10 _7 M) 28 ⁇ 0.5 26 ⁇ 0.3 7.5 ⁇ 0.3 TNF (lOU/ml) 21 ⁇ 0.3 32.5 ⁇ 0.0 9 ⁇ 1.0 TNF + FMLP 36 ⁇ 0.5 46 ⁇ 0.5 21 ⁇ 0.3
  • FMLP N-formyl-methionyl-leucyl-phenylalanine
  • TNF-alpha an agent that also activates neutrophils.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte de façon générale à un procédé permettant d'interférer avec diverses activités des cellules sanguines chez un mammifère et servant ainsi à inhiber, à réduire ou à réguler de toute autre manière une réaction inflammatoire et/ou à réduire, à empêcher et/ou à inhiber l'adhésion des cellules sanguines à des cellules endothéliales. L'invention se rapporte également à des compositions pharmaceutiques utilisables dans un tel procédé et comprenant la protéine de membrane de granule (GMP) 140, se trouvant dans les granules alpha des plaquettes sanguines, et/ou ses dérivés et des protéines analogues.
PCT/AU1990/000573 1989-11-30 1990-11-30 Facteurs anti-inflammatoires et anti-adhesifs WO1991007993A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPJ765189 1989-11-30
AUPJ7651 1989-11-30
AUPK1027 1990-07-05
AUPK102790 1990-07-05

Publications (1)

Publication Number Publication Date
WO1991007993A1 true WO1991007993A1 (fr) 1991-06-13

Family

ID=25643789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1990/000573 WO1991007993A1 (fr) 1989-11-30 1990-11-30 Facteurs anti-inflammatoires et anti-adhesifs

Country Status (1)

Country Link
WO (1) WO1991007993A1 (fr)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006863A1 (fr) * 1991-09-30 1993-04-15 Biogen, Inc. Inhibition du retrecissement vasculaire par l'utilisation d'anticorps anti-padgem
WO1994005314A1 (fr) * 1992-09-08 1994-03-17 Centocor, Inc. Inhibiteurs peptidiques de l'adhesion des leucocytes
WO1994017193A3 (fr) * 1993-01-25 1994-11-10 Dana Farber Cancer Inst Inc Selectine l et selectine p obtenues par echange de domaines et leurs utilisations
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5464935A (en) * 1992-05-28 1995-11-07 Centocor, Inc. Peptide inhibitors of selectin binding
US5602230A (en) * 1992-05-28 1997-02-11 Centocor, Inc. Peptide inhibitors of selectin binding
US5605821A (en) * 1989-03-08 1997-02-25 Board Of Regents Of The University Of Oklahoma Expression control sequences of the P-selectin gene
US5618785A (en) * 1993-11-22 1997-04-08 Centocor, Inc. Peptide inhibitors of selectin binding
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US5658880A (en) * 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5660992A (en) * 1993-06-16 1997-08-26 Glycomed Incorporated Sialic acid/fucose based assay reagents and assay methods
US5679321A (en) * 1993-06-17 1997-10-21 Glycomed Incorporated Sialic acid/fucose based medicaments
US5710123A (en) * 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
US5753617A (en) * 1992-09-08 1998-05-19 Centocor, Inc. Peptide inhibitors of cellular adhesion
US5753631A (en) * 1990-06-15 1998-05-19 Cytel Corporation Intercellular adhesion mediators
US5789385A (en) * 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5837689A (en) * 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US6111065A (en) * 1991-12-18 2000-08-29 Centocor, Inc. Peptide inhibitors of inflammation mediated by selectins
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6528487B1 (en) 1991-09-10 2003-03-04 Centocor, Inc. Peptide inhibitors of inflammation mediated by selectins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4653389A (en) * 1988-11-14 1990-06-12 Brigham And Women's Hospital Cloned genes which encode elam-1 and fusion proteins thereof, the protein products expressed therefrom, pharmaceutical compositions and the use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4653389A (en) * 1988-11-14 1990-06-12 Brigham And Women's Hospital Cloned genes which encode elam-1 and fusion proteins thereof, the protein products expressed therefrom, pharmaceutical compositions and the use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BEVILACQUA MICHEAL P, et al., "Endothelial Leukocyte Adhesion Molecule 1: An Inducible Receptor for Neutrophils Related to Complement regulatory Proteins and Lectins' SCIENCE (Washington D.C. 1883-), V 243 (4895), p. 1160-5. 3 March 1989. *
CHEMICAL ABSTRACTS, Vol. 113, No. 19, 170246d, issued 1990, GRABER, NORMA et al, (Dep. Immunol., Otsuka America Pharm. Inc. Rockville. MD 20850 USA). "T-Cells Bind to Cytokine-Activated Endothelial Cells via a Novel, Inducible Sia-Adhesion Molecule-1"; & J. IMMUNOL. 1990. 145 (3), 819-30 (Eng.), page 556. *
GAMBLE, JENNIFER, R. et al., "Prevention of Activated Neutrophil Adhesion to Endothelium by Soluble Adhesion Protein GMP 140", Science (Washington D.C. 1883-) V 249 (4967), 27 July 1990, p. 414-417. *
GENG, JIAN-GUO; et al., "Rapid Neutrophil Adhesion to Activated Endothelium Medicated by GMP-140", NATURE (London), V 343 (6260), p. 757-60, 22 February 1990. *
MCEVER, RODGER, P. "Properties of GMP-140, an Inducible Granule Membrane Protein of Platelets and Endothelium", BLOOD CELLS, v 16(1), p. 73-83, 1990. *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834425A (en) * 1989-02-21 1998-11-10 Dana-Farber Cancer Institute, Inc. Use of chimeric selectins as simultaneous blocking agents for component selectin function
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5852175A (en) * 1989-03-08 1998-12-22 The Board Of Regents Of The University Of Oklahoma P-selectin glycoprotein ligand blocking antibodies
US5880091A (en) * 1989-03-08 1999-03-09 The Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5605821A (en) * 1989-03-08 1997-02-25 Board Of Regents Of The University Of Oklahoma Expression control sequences of the P-selectin gene
US5753631A (en) * 1990-06-15 1998-05-19 Cytel Corporation Intercellular adhesion mediators
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6667036B2 (en) 1991-02-05 2003-12-23 The Board Of Regents Of The University Of Oklahoma Methods of treatment using antibodies to P-selectin glycoprotein ligand
US6506382B2 (en) 1991-02-05 2003-01-14 The Board Of Regents Of The University Of Oklahoma Method for inhibiting reperfusion injury using antibodies to P-selectin glycoprotein ligand
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US6528487B1 (en) 1991-09-10 2003-03-04 Centocor, Inc. Peptide inhibitors of inflammation mediated by selectins
WO1993006863A1 (fr) * 1991-09-30 1993-04-15 Biogen, Inc. Inhibition du retrecissement vasculaire par l'utilisation d'anticorps anti-padgem
US6111065A (en) * 1991-12-18 2000-08-29 Centocor, Inc. Peptide inhibitors of inflammation mediated by selectins
US5602230A (en) * 1992-05-28 1997-02-11 Centocor, Inc. Peptide inhibitors of selectin binding
US5464935A (en) * 1992-05-28 1995-11-07 Centocor, Inc. Peptide inhibitors of selectin binding
US5753617A (en) * 1992-09-08 1998-05-19 Centocor, Inc. Peptide inhibitors of cellular adhesion
US5916876A (en) * 1992-09-08 1999-06-29 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
WO1994005314A1 (fr) * 1992-09-08 1994-03-17 Centocor, Inc. Inhibiteurs peptidiques de l'adhesion des leucocytes
US5710123A (en) * 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
US5808025A (en) * 1993-01-25 1998-09-15 Dana-Farber Cancer Institute, Inc. Chimeric selectins as simultaneous blocking agents for component selectin function
WO1994017193A3 (fr) * 1993-01-25 1994-11-10 Dana Farber Cancer Inst Inc Selectine l et selectine p obtenues par echange de domaines et leurs utilisations
US5789385A (en) * 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5837689A (en) * 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5750508A (en) * 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
US5660992A (en) * 1993-06-16 1997-08-26 Glycomed Incorporated Sialic acid/fucose based assay reagents and assay methods
US5658880A (en) * 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5679321A (en) * 1993-06-17 1997-10-21 Glycomed Incorporated Sialic acid/fucose based medicaments
US5618785A (en) * 1993-11-22 1997-04-08 Centocor, Inc. Peptide inhibitors of selectin binding

Similar Documents

Publication Publication Date Title
WO1991007993A1 (fr) Facteurs anti-inflammatoires et anti-adhesifs
Sharma et al. Involvement of nitric oxide in acute spinal cord injury: an immunocytochemical study using light and electron microscopy in the rat
US7811985B2 (en) Therapeutic fibrin-derived peptides and uses thereof
US5177189A (en) Polypeptide analogs of Apolipoprotein E
EP2480567B1 (fr) Polypeptides c-terminal de la thrombin et leurs utilisations pour traiter des conditions inflammatoires et de la coagulation
US5708145A (en) Immunglobulins reactive with protegrins
Van Lent et al. In vivo role of phagocytic synovial lining cells in onset of experimental arthritis
JPH08502024A (ja) インターフェロン−αとヒスタミン、セロトニン、アミン類または相当するレセプター活性を有する物質とを含有するナチュラルキラー細胞（ＮＫ細胞）活性化用製剤
EP1670510A1 (fr) Anticorps diriges contre les annexines, leur utilisation a des fins therapeutiques et diagnostiques, utilisation des annexines a des fins therapeutiques et diagnostiques
HU197358B (en) Process for producing human antitumour substance and pharmaceuticals comprising same
Farries et al. Competition for binding sites on C3b by CRI, CR2, MCP, factor B and factor H
US4702908A (en) Composition containing platelet factor 4 and method for restoring suppressed immune responses
AU2004247737B2 (en) Platelet glycoprotein IB alpha variant fusion polypeptides and methods of use thereof
WO2000005263A2 (fr) Composes utilises dans le traitement de l'inflammation
AU2008282937A1 (en) Methods of treating blood cell depletion
US20060258570A1 (en) Decorin proteoglycan inhibitor of fibrinogen blood clotting
De Prost Pentoxifylline: a potential treatment for thrombosis associated with abnormal tissue factor expression by monocytes and endothelial cells
Issekutz et al. Effect of nonsteroidal anti-inflammatory agents on immune complex-and chemotactic factor-induced inflammation
Benyhe et al. [3H] Dynorphin1–8 binding sites in frog (Rana esculenta) brain membranes
Jepsen et al. Zinc Ions Inhibit Factor I‐Mediated Release of CR1‐Bound Immune Complexes and Degradation of Cell‐Bound Complement Factors C3b and C4b
JPH1072364A (ja) 癌転移抑制剤
WO1993005394A1 (fr) Identification de composes membranolytiques et precurseurs de ceux-ci
Edgington et al. MOLECULAR CLONING OF HUMAN TISSUE FACTOR cDNA
Morrissey et al. DIFFERENTIAL EXPRESSION AND SUBCELLULAR LOCALIZATION OF TISSUE FACTORIN A CONSTITUTIVE VERSUS AN INDUCIBLE CELL TYPE
CA2508691A1 (fr) Utilisation de complements inhibiteurs pour le traitement de lesions de la moelle epiniere

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载